Introduction {#Sec1}
============

Breast cancer is an important public health problem in developed countries as it is one of the most common cancers, being the most if only the female population is considered^[@CR1]^. The incidence is decreasing every year, which is partly due to early detection programs^[@CR2]^.

In the last decades, cellular *in vitro* experiments and *in vivo* models have evaluated the role of vitamin D in the development of breast cancer, finding a protective anticancer role of 1,25(OH)D3^[@CR3]^. It has been demonstrated that treating breast cancer cells with 1,25(OH)D3 induces two beneficial effects: an anti-proliferative effect^[@CR4]^ and a pro-apoptotic effect^[@CR5],[@CR6]^. The former is linked to the suppression of growth stimulatory signals and the potentiation of growth inhibitory signals, whilst the second one is explained by the bcl-2 family proteins. The interaction between vitamin D and its receptors induces an increase in the expression of pro-apoptotic family member (bax and bak protein) and simultaneously a decrease of anti-apoptotic (bcl-2/bcl-XL)^[@CR6]^. In addition, the breast tissue contains the 1-α-hydroxylase, allowing for the generation of the active vitamin D metabolite (1,25 dihydroxyvitamin D) from the circulating precursor (25 hydroxyvitamin D). As vitamin D receptors are found in the breast^[@CR6]^, an autocrine role of vitamin D has been suggested^[@CR7]^.

Despite this biological background, literature shows inconsistent results^[@CR8]--[@CR16]^ (Table [1](#Tab1){ref-type="table"}). Several additional observational studies have appeared since the last meta-analysis publication (including articles until 2013). The main purpose of the present meta-analysis is to update the relationship between vitamin D exposure and breast cancer risk by adding the studies published more recently. Thus sixty-eight observational studies: thirty of these were case-control, twenty-one were nested case-control and the remaining were cohort studies.Table 1RR of breast cancer and vitamin D in previous meta-analysis.SourceType of vitamin DNumber of included studiesType of included studiesRR (95%IC)Bauer SR *et al*. (2013)25(OH)D9Cohort & nested case-control studies0.9 (0.97--1.00)Chen P *et al*. (2010)25(OH)D21Case control, cohort, & cross-sectional studies0.55 (0.38--0.80)Intake of vitamin D0.91 (0.85--0.97)1,25(OH)2D0.99 (0.68--1.44)Chen P *et al*. (2013)25(OH)D21Nested case-control & retrospective studies0.86 (0.75--1.00)Population based case control studies0.35 (0.24--0.52)Hospital based case-control studies0.08 (0.08--0.33)Gandini S *et al*. (2011)25(OH)D10Case-control0.83 (0.79--0.87)Nested case-control & cohort studies0.97 (0.92--1.03)Gissel T *et al*. (2008)Intake of vitamin D6Cross sectional, Case-control, cohort & r&omized-control trials0.98 (0.93--1.03)Kim Y and Je Y. (2014)Intake of vitamin D24Cohort & nested case-control studies0.95 (0.88--1.01)25(OH)D0.92 (0.83--1.02)Wang D *et al*. (2013)25(OH)D14Cohort & nested case-control studies0.84 (0.75--0.95)Mohr SB *et al*. (2011)25(OH)D11All0.61 (0.47--0.80)Case-control studies0.87 (0.77--0.99)Nested case-control studies0.41 (0.31--0.56)Yin L *et al*. (2010)25(OH)D9All0.73 (0.60--0.88)Nested case-control0.92 (0.82--1.04)Case- control0.59 (0.48--0.73)

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Firstly, the following inclusion criteria were defined: we looked for cohort or case-control studies performed in humans, which reported, at least, one relative risk (RR) or odds ratio (OR) with confidence interval at 95%. (95% CI)

We began our search in Pub-Med, Scopus and Web of Science database using "breast cancer" and "vitamin D" as keywords, finding 2313 articles. After having read the title and abstract, 2123 articles that did not meet the above criteria were eliminated. Next, we carried out a more exhaustive and complete reading, which allowed us to reject another additional 69 articles (Fig. [1](#Fig1){ref-type="fig"}). Finally, sixty eight studies meeting our inclusion criteria were identified: fifty one case-control^[@CR10],[@CR17]--[@CR65]^ and seventeen cohort studies^[@CR65]--[@CR81]^. Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} summarize the main characteristics of the included articles.Figure 1Flowchart which describes the methodology of selection of the articles.Table 2Studies included in our meta-analyses of blood 25-hydroxyvitamin D and breast cancer risk.Nested Case-ControlCountryExpositionGroupOR 95% CINo. of participantsAge at baseline^a^Follow-up periodUpper vs lower cut off levelsAdjusted by Time of blood drawAlmquist M *et al*.(2010)^£,¥,§,φ^Sweden25(OH)D3All0.99 (0.72--1.36)152457 years1991--2006≥106 vs ≤70 ng/mLYes25(OH)D3 + D2All1.01 (0.73--1.40)≥107 vs ≤71 ng/mL25(OH)D3PRE1.58 (0.77--3.25)≥106 vs ≤70 ng/mLPOST0.88 (0.60--1.28)≥107 vs ≤71 ng/mL25(OH)D3 + D2PRE1.74 (0.84--3.60)≥106 vs ≤70 ng/mLPOST0.88 (0.60--1.29)≥107 vs ≤71 ng/mLAmir E *et al*. (2012)^£^Canada25(OH)DAll0.86 (0.62--1.21)108753.6 years1992--1997≥34.4 vs \<12 ng/mLNoBertone-Johnson ER *et al*. (2005)^£,¥,§^USA25(OH)DAll0.73 (0.49--1.07)142552.7 cases 57.1 controls1989--1996≥48 vs \<20 ng/mLNo1,25(OH)DAll0.76 \[0.52--1.11\]≥38.2 vs \<28.5 ng/mLChlebowski RT *et al*. (2008)^€,£,§,ǂ,\$^USA25(OH)DPOST0.82 (0.60--1.12)213450--79 years1995--2002≥27.04 vs \<12.96 ng/mLYesDeschasaux M *et al*. (2016)^£,\ ¥,ǂ,φ^France25(OH)DAll0.98 (0.60--1.61)69949.3 cases 49.1 controls1994--2007≥23.5 vs \<11.4 ng/mLYesEliassen AH *et al*. (2011)^£,¥^USA25(OH)DAll1.20 (0.88--1.63)182745 cases 44.9 controls1996--2007≥30.6vs \<18.4 ng/mLNoER+1.21 (0.84--1.75)ER−1.31 (0.63--2.74)Eliassen AH *et al*.(2016)^£,¥^USA25(OH)DAll0.84 (0.58--1.21)301256.7 cases 56.8 controls1989--2010≥32.7 ng/ml vs \<17.5NoER+0.89 (0.74--1.08)≥30 ng/ml vs \<30ER−0.87 (0.63--1.20)Engel P *et al*. (2010)^€,£,\ ¥,\ ǂ^France25(OH)DAll0.73 (0.55--0.96)190856.9 years1995--2005\>27 vs \<19.8 ng/mlYesPRE0.37 (0.12--1.15)POST0.80 (0.60--1.07)Freedman M *et al*. (2008)^€,£,¥¥,§^USA25(OH)DPOST1.04 (0.72--1.51)201055--74 years1993--200533.7 vs 18.3 ng/mLYesHiatt RA *et al*. (1998)^¥,φ^USA1,25(OH)2DAll1.00 (0.20--3.40)192\>55 years1980--1991≥51 vs \<32 pg/mlNoKim Y *et al*. (2014)^£,¥,\$^USA25(OH)DWhite0.13 (0.03--0.71)141468.5 cases 68.4 controls2001--2006\>0 vs 0 ng/mLYesAfrican-american1.35 (0.65--2.78)Hawaian1.35 (0.23--7.69)Japanese1.04 (0.51--2.13)Latino1.11 (0.51--2.44)Kühn T *et al*. (2013)^£,¥,ǂ,φ^Europe25(OH)DAll1.07 (0.85--1.36)278250.7 years1992--2006\>63 vs ≤39.3nmol/LNoER+0.97 (0.67--1.38)ER−0.97 (0.66--1.42)McCullough ML *et al*.(2009)^£,¥,\$^USA25(OH)DAll1.09 (0.70--1.68)103269.5 cases 69.4 controls1998--2005\>76.2vs \<36.7 nmol/mlYesER+1.15 (0.80--1.65)\>64.2 vs \<45.9 nmol/mlER−0.95 (0.43--2.06)Mohr SB *et al*. (2013)^\$^USA25(OH)DAll0.84(0.56--1.25)120039.6 years1994--2009≥35.2 vs ≤14.9 ng/mLNoNeuhouser ML *et al*. (2012)^£,ǂ^USA25(OH)DPOST0.94 (0.70--1.28)216050--79 years1994--2005≥25.96vs ≤14.68 ng/mLNoRejnmark L *et al*. (2009)^\#^Denmark25(OH)DAll0.52 (0.32--0.85)56258 years2003--2007\>33.6 vs \<24 ng/mLNoPRE0.38 (0.15--0.97)POST0.71 (0.38--1.30)Scarmo S *et al*. (2013)^£,¥,§^USA&Sweden25(OH)DAll0.94 (0.76--1.16)452534--69 years1985--2007 1995--2010N.A. (Quintiles)NoPRE0.67 (0.48--0.92)POST1.21 (0.92--1.58)Shirazi L *et al*. (2016)^€,£,\ ¥,§^Sweden25(OH)D3All0.97 (0.75--1.25)152046--73 years1991--1996/2006≥98nmol/L vs ≤76nmol/LYesWang J *et al*. (2014)^£,¥^USA25(OH)DAll0.95 (0.67--1.36)116845 years\>= 5.59 vs \<3.76nmol/LNo**Case-ControlCountryExpositionGroupOR 95% CINo. of participantsAge at baselineFollow-up periodUpper cut off levels**Abbas S *et al*. (2009)^£,¥,φ^Germany25(OH)DPRE0.45 (0.29--0.70)88442.1 cases 41.6 controls1992--1995≥60 vs \<30nmol/LYesER+0.56 (0.31--1.00)ER−0.40 (0.20--0,81)Abbas S *et al*. (2008)^£,¥,§^Germany25 (OH)DPOST0.31 (0.24--0.42)275963.6 cases\
63.5 controls2001--2005\> = 75 vs \<30nmol/LYesAlipour S *et al*. (2014)^€,\ ¥^Iran25 (OH)DAll0.33 (0.12--0.91)50044.2 cases\
43.2 controlsN.A.\>35 ng/ml vs \<12.5 ng/mlNoBilinski K *et al*. (2012) ^€,φ^Australia25(OH)DAll0.43 (0.23--0.77)106655.4 cases\
55.5 controls2008--2011≥75nmol/L vs \<25nmol/mLYes\<50years0.29 \[0.08--1\]≥50 years0.45 \[0.23--0.71\]Chen P *et al*. (2013)^€,\ ¥,§^China25(OH)DAll0.11 (0.07--1.17)117353.0 cases\
55.3 controls2005--2008\>17.9 ng/ml vs \<10.4 ng/mlYesColagar AH *et al*. (2015)^\#^Iran25(OH)DAll0.26 (0.13--0.50)26148.7 cases\
47.0 controls2009--2013≥16 vs \<9 ng/mLNoCrew KD *et al*. (2009) ^€,£,¥,§,ǂ,\$^USA25(OH)DAll0.56 (0.41--0.78)210158.6 cases\
56.1 controls1996--1997≥40 vs \<20 ng/mLYesPRE0.83 \[0.36--1.30\]POST0.46 \[0.09--0.83\]Fedirko V *et al*. (2012)^£,¥¥,§,ǂ,φ^Mexico25(OH)D3All0.53 (0.36--0.78)207453.1 cases\
51.3 controls2004--2007\>25 vs ≤20 ng/mLYesPRE0.40 (0.30--0.81)POST0.55 (0.33--0.90)Jamshidinaein Y *et al*. (2016)^£,§,φ,\$^Iran25(OH)DAll0.26 (0.12--0.59)27050.4 cases\
50.0 controls2013--2014≥29.5 vs \<10.30 ng/mlYesPRE0.25 (0.09--0.69)POST0.42(0.15--1.17)Janowsky EC *et al*. (1999)^€^USA1,25(OH)2DAll0.31 (0.17--0.59)331NA1990--1991≤34.6 vs\>63.6pmol/mlYesLowe LC *et al*.(2005)^€^UK25(OH)DAll0.17 (0.07--0.43)35858.0 cases\
58.0 controls1998--2003≥150 vs ≤50 nMYesOliveira-Sediyama CM *et al*.(2016)^ǂ^Brazil25(OH)DAll0.34 (0.16--0.71)37854.0 cases\
47.5 controlsNA≥20vs \<20 ng/mLNoPark S *et al*. (2015)^€,£,\ ¥,§^Korea25(OH)DAll0.82 (0.75--0.90)2076750.7 cases\
49.7 controls2006--2012≥20 vs \<20 ng/mLYesPRE0.84 (0.74--0.96)POST0.82 (0.73--0.93Sofi NY *et al*. (2016)^\#^India25(OH)DAll0.40 (0.14--1.11)20045.0 cases\
46.0 controls2014--2015≥20 ng/mL vs \<20 ng/mLNoSofi NY *et al*. (2018)^\#^India25(OH)DAll0.42 (0.20--0.83)40045.0 cases\
47.0 controls2015--2017≥20 ng/mL vs \<20 ng/mLNoYao S *et al*. (2011)^€,£,¥^USA25(OH)DAll0.37 (0.27--0.51)1153NA2003--2008≥30 vs \<20 ng/mLYesPRE0.57 (0.34--0.93)POST0.29 (0.19--0.45)Yousef FM *et al*. (2013)^€,£,φ^Saudi Arabia25(OH)DAll0.16 (0.07--0.42)24018--75 years2009≥20 vs \<10 ng/mLNoOrdoñez-Mena JM *et al*. (2016)^€,£,ǂ,φ^Europe25(OH)DPOST0.73 (0.22--2.43)252\> = 60 years1992--2000\>50 vs \<30 nmol/LYes**CohortCountryExpositionGroupRR 95% CICases (No. of participants)Age at baselineFollow-up periodUpper cut off levels**Skaaby T *et al*. (2014)^£,ǂ,φ^Denmark25(OH)DAll1.1 (0.7--1.71)159 (5606)18--71 years1993--2008N.A. (Quartiles)YesO´Brien KM (2017) et al^€,£,\ ¥,§,ǂ,φ,\$^USA25(OH)DAll0.79 (0.63--0.98)1600 (3422)35--74 years2003--2009\>38 vs \<24.6 ng/mLYesOrdonez-Mena JM *et al*. (2013)^€,£,ǂ,φ^Germany25(OH)DAll1.08 (0.72--1.6)137 (5261)50--74 years2000--2002\<30 vs \>55 nmol/L\*NoPalmer JR *et al*. (2016)^€,£,\ ¥,§^USA (African American Women)25(OH)DAll0.81 (0.68--0.96)1454 (2856)21--69 years2012--2017≥49 vs \<21 ngNoOrdonez-Mena JM *et al*. (2016)^€,£,\ ǂ,φ^Germany25(OH)DPOST1.35 (0.38--2.27)63 (4990)63 years2000--2002\>50 vs \<30nmol/LYesOrdonez-Mena JM *et al*. (2016)^€,£,ǂ,φ^Norway25(OH)DPOST2.63 (0.82--8.33)89 (2471)62 years1994--1995\>50 vs \<30nmol/LYes^a^Mean or range of age.Adjusted by: ^€^age; ^£^BMI; ^¥^reproductive factors (menopausal status, age at menopause, age at menarche, parity, etc); ^§^hormone therapy; ^ǂ^physical activity; ^φ^educative or socioeconomic variables; ^\$^race or sun exposure.^\#^Unadjusted.Abbreviations: CI = confidence interval; POST = postmenopausal; PRE = premenopausal; OR = odds ratio; NA: Not available.Table 3Studies included in our meta-analyses of dietary or supplements vitamin D and breast cancer risk.Case-ControlCountryExpositionGroupOR (95% CI)No. of participantsAge at baselineFollow-up periodUpper vs lower cut off levelsAbbas S *et al*. (2007)^€,£,¥^GermanyDietary Vitamin DPRE0.50 (0.26--0.96)94441.7 cases\
41.6 controls1992--1995≥200 vs \<80 IU/dayAnderson LN *et al*. (2010)^€,¥,ǂ,φ^CanadaTotal vitamin D intakeAll0.99 (0.78--1.26)657256 years2002--2003≥15 vs \<2.5 mg/dayDietary Vitamin D1.13 (0.88--1.45)≥10 vs \<2.5 mg/dayVitamin D supplement0.76 (0.59--0.98)≥10 vs 0 mg/dayAnderson LN *et al*. (2011)^€^CanadaVitamin D supplementAll0.80 (0.60--1.08)361656 years2002--2003\>400 vs 0 IU/dayTotal Vitamin D intake0.87 (0.71--1.06)≥600 vs \<200 IU/dayBidgoli SA *et al*. (2014)^\#^IranVitamin D supplementPRE0.89 (0.84--0.95)17636.5 cases 34.2 controls2010--2012Yes vs NoJamshidinaein Y *et al*. (2016)^€,£,¥,§,φ^IranDietary vitamin DAll0.38 (0.18--0.83)27050.4 cases 50 controls2013--2014NA (Quartile)Dietary vitamin DPRE0.39 (0.15--1.00)Dietary vitamin DPOST0.40 (0.15--1.12)Total vitamin D intakeAll0.52 (0.25--1.14)Total vitamin D intakePRE0.36 (0.13--1.06)Total vitamin D intakePOST0.70 (0.27--1.82)Kawase T *et al*. (2010)^£,¥,§,ǂ^JapanDietary Vitamin DAll0.76 (0.63--0.90)540920--792001--2005\>6.66 vs \<2 mg/dayPRE0.65 (0.50--0.86)POST0.83 (0.64--1.07)Lee MS *et al*. (2011)^€,£,¥,φ^TaiwanDietary Vitamin DAll0.57 (0.28--1.19)40052.5 cases 48.9 controls2004--2005\>5 vs \<2 mg/dayDietary Vitamin DPRE0.38 (0.14--0.98)Dietary Vitamin DPOST0.60 (0.20--1.69)Total vitamin D intakeAll0.52 (0.25--1.07)NA (Quartile)Total vitamin D intakePRE0.47 (0.18--1.23)Total vitamin D intakePOST0.68 (0.23--1.27)Levi F *et al*.(2001)^€,£,¥,φ^SwitzerlandVitamin D supplementAll1.43 (0.90--2.26)73123--741993--1999≥2.7 vs \<1.4 mg/dayLeung *et al*.(2016)^€^ChinaVitamin D supplementAll0.78 (0.63--0.98)323612\>182000--2011≤15 DDDPotischman N *et al*. (1999)^€,¥,§,φ^USADietary Vitamin DAll0.98 (0.80--1.20)201920--441990--1992≥400 vs \<0 IURollison DE *et al*. (2012)^€,£,¥,§,ǂ^USADietary Vitamin DAll1.35 (1.15--1.60)483924--791999--20047.71 vs \<3.06 mg/dayVitamin D supplementAll0.79 (0.65--0.96)24--79 years1999--20040 vs\>10 mg/dayRossi M *et al*. (2009)^€,£,¥,§,φ^ItalyDietary Vitamin DAll0.76 (0.58--1.00)515755 years cases 56 controls1991--1994\>3.57 vs ≤3.57 mgPRE0.80 (0.64--0.99)POST0.78 (0.66--0.92)Salarabadi A *et al*. (2015)^\#^IranVitamin D supplementPRE0.53 (0.14--1.96)152NA2012--2014Yes vs No**CohortCountryExpositionGroupRR (95% CI)Cases/TotalAge at baselineFollow-up periodUpper cut off levels**John EM *et al*. (1999)^€,£,¥,ǂ,φ^USADietary vitamin DAll0.85 (0.59--1.24)190/500925--741971--1992≥200 vs \<100 IU/dayVitamin D supplementAll0.89 (0.60--1.32)25--741971--1993Daily vs neverTotal vitamin D intakeAll0.86 (0.61--1.2)25--741971--1994≥200 or daily suppl vs \<100 IU/day without daily supplShin MH *et al*. (2002)^€,£,¥,ǂ^USATotal vitamin D intakePRE0.89 (0.68--1.15)3482/88 69146.71980--1996\>500 vs ≤150 IU/dayPOST0.93 (0.8--1.08)Dietary Vitamin DPRE0.84 (0.59--1.18)POST0.86 (0.7--1.05)Lin J *et al*. (2007)^€,£,¥,§,ǂ^USATotal vitamin D intakePRE0.65 (0.42--1)1019/3148755 (≥45)1993--2003≥548 vs \<162 IU/dPOST1.30 (0.97--1.73)Dietary vitamin DPRE1.02 (0.69--1.53)≥319 vs \<142 IU/dPOST1.22 (0.95--1.55)Vitamin D supplementPRE0.76 (0.5--1.17)≥400 vs 0 IU/dPOST0.87 (0.68--1.12)Robien K *et al*. (2007)^€,£,¥,§,φ^EEUUVitamin D supplementPOST0.89 (0.74--1.08)2440/3432161 (55--69)1986--2004≥800 IU/d vs NoDietary Vitamin DPOST0.55 (0.24--1.22)≥800 vs \<400 IU/dTotal vitamin D intakePOST0.89 (0.77--1.03)≥800 vs \<400 IU/dKuper H *et al*. (2009)^€,£,¥,§,ǂ^SwedenDietary vitamin DAll0.90 (0.80--1.1)848/4188930--491991--2003N.A. (Quartile)Cadeau C *et al*. (2015) ^€,£,¥,§,ǂ^FranceVitamin D supplementAll1.10 (0.92--1.31)2482/5740340--651995--2008Current vs neverER+1.23 (1--1.51)40--651995--2008Current vs neverER−0.93 (0.55--1.55)40--651995--2008Current vs neverAbbas S *et al*. (2013)^€,¥,§,ǂ,φ^EuropeDietary vitamin DAll1.04 (0.94--1.14)7760/31998550.21992--2005≥5.46 vs \<1.85 mg/dayPRE1.07 (0.87--1.32)≥5.46 vs \<1.85 mg/dayPOST1.02 (0.9--1.16)≥5.46 vs \<1.85 mg/dayMcCullough ML *et al*. (2005)^€,¥,§,ǂ,φ^USATotal vitamin D intakePOST0.94 (0.8--1.1)2855/6856750--741992--2001\>700 vs ≤100 IU/dayDietary vitamin DPOST0.87 (0.75--1)\>300 vs ≤100 IU/dayEdvarsen K *et al*. (2011) ^€,£,¥,§^NorwayDietary vitamin DAll1.07 (0.87--1.32)948/4181140--701997--200712.31 vs \<3.99 mg/dayFrazier *et al*. (2004)^€,£,¥,§^USADietary vitamin DAll0.92 (0.66--1.27)838/4735534--511989--1998591 vs 159.6 IU/dayEngel P et al. (2011)^£,¥,§,ǂ^FranceTotal vitamin D intakeAll0.94 (0.86--1.03)2871/6772141.8--721990--2008\>113 vs \<80 IU/dayPRE1.03 (0.85--1.25)POST0.92 (0.86--1.03)**Nested Case-ControlCountryExpositionGroupOR (95% CI)No. of participantsAge at baselineFollow-up periodUpper vs lower cut off levels**Simard A *et al*. (1991)^\#^CanadaDietary Vitamin DAll2.79 (0.85--9.15)43040--591981--1983\>200 vs \<50 IU/dayKim Y *et al*. (2014)^£,¥,ǂ^USAVitamin D supplementWhite1.29 (0.75--2.23)141467.82001--2010\> = 16 ng/mL vs \<16 ng/mLAfrican-american0.29 (0.12--0.70)Hawaian0.46 (0.16--1.34)Japanese1.32 (0.90--1.93)Latino0.85(0.46--1.56)PRE1.03 (0.85--1.25)POST0.92 (0.86--1.03)^a^*Mean or range of age*.Adjusted by: ^€^age; ^£^BMI; ^¥^reproductive factors (menopausal status, age at menopause, age at menarche, parity, etc); ^§^hormone therapy; ^ǂ^physical activity; ^φ^educative or socioeconomic variables; ^\$^race or sun exposure.^\#^Unadjusted.*Abbreviations: CI* = *confidence interval; POST* = *postmenopausal; PRE* = *premenopausal;* OR = odds ratio*; NA: Not available*.

Data extraction {#Sec4}
---------------

The following step was to create a database to gather all relevant information extracted from each article: year of publication, author, journal, follow up, country, sample size, exposure levels, units of measure, data for the creation of the contingency table and RR/OR with 95% CI; as well as a section to assess the quality of the study using the STROBE scale^[@CR82]^.

Statistical analysis {#Sec5}
--------------------

Statistical analysis was performed separately for cohort and case-control studies. In the case control studies a sensitivity analysis was also carried-out including only nested case-control studies. We performed separate analyses for any type of vitamin D exposure reported in at least three studies: 25(OH)D, dietary intake of vitamin D, 1,25(OH)2D and vitamin D supplements.

The ways that doses or levels of vitamin D were reported in each individual article were not standardized across studies (for instance, some papers reported vitamin D levels in quartiles; others in tertiles, and so on), making it difficult to extract them in an analyzable form. Therefore, in order to provide a consistent criterion of comparability, we selected the OR or RR reported for the highest category compared to the lowest one.

Regarding the type of breast cancer, we analyzed all invasive breast cancers together, and breast cancer stratified according to the cancer estrogen receptor status and woman's menopausal status. Pooled OR or RR were estimated by weighting individual OR/RR by the inverse of their variance. OR or RR heterogeneity was measured using Q and I^2^ statistics^[@CR83]^. A fixed-effect model was preferred if the Q statistic was higher than 0.1 or I^2^ lower than 25%, indicating no relevant heterogeneity; a random-effect model was otherwise chosen^[@CR84]^. The presence of small-study bias was explored with Rosenthal model and with Egger test^[@CR85]^; due to the low sensitivity of Egger test, the cut-off was set at p = 0.1. Funnel plots^[@CR86]^ were applied to detect publication bias.

An analysis of influence was performed via the re-estimation of pooled OR/RR by removing one study at a time. Studies that, when removed, strongly changed the OR/RR would be considered as highly influential. Results are displayed as forest plots showing OR/RR and their 95% confidence intervals for each individual study and for the pooled result. Cumulative meta-analyses were carried out to deem the stability of the OR/RR estimates. In order to do that, all studies considered were arranged from oldest to neweest. Then an OR/RR estimate was obtained for the two eldest studies; another for the three eldest, and so on, adding a study each time. Results are reported as forest plots.

All the statistical analyses were carried out with the package Stata 14/SE (Stata Corporation, College Station, TX, US).

Results {#Sec6}
=======

Relationship between 25(OH) D and breast cancer {#Sec7}
-----------------------------------------------

Twenty-nine case control studies were analyzed to study the relationship between 25 (OH) D and breast cancer^[@CR10],[@CR19]--[@CR22],[@CR25],[@CR27],[@CR29]--[@CR35],[@CR38],[@CR42],[@CR44]--[@CR46],[@CR48],[@CR49],[@CR51],[@CR55],[@CR56],[@CR58]--[@CR63]^ obtaining a pooled OR of 0.65 (95%CI: 0.56--0.76) (Fig. [2a](#Fig2){ref-type="fig"}, Table [4](#Tab4){ref-type="table"}). This value was calculated using the random effects model because of the high heterogeneity (I^2^ = 77.76%) of the fixed-effect. Although Egger test cannot rule out a small-study effect (p = 0.001), no study shows a relevant influence. The funnel plot shows asymmetry (Supplementary Fig. [1a](#MOESM1){ref-type="media"}), indicating either publication bias or heterogeneity that cannot be explained by a random-effect meta-analysis. Rosenthal model shows that 1194 negative studies would be needed to lose statistical significance. In order to further clarify the heterogeneous result, we carried out a sensitivity analysis including only nested case-control studies^[@CR21],[@CR22],[@CR25],[@CR31]--[@CR34],[@CR42],[@CR45],[@CR46],[@CR51],[@CR55],[@CR56],[@CR59]^ reaching a pooled OR = 0.92 (95%CI: 0.83--1.01) (Fig. [2b](#Fig2){ref-type="fig"}) with I^2^ = 15.87%, Q-based p value = 0.22 and a very symmetrical-looking funnel plot (Supplementary Fig. [1b](#MOESM1){ref-type="media"}).Figure 2(**a**) Forest plot for the relationship between 25(OH)D and breast cancer in case control studies. (**b**) Forest plot for the relationship between 25(OH)D and breast cancer in nested case control studies.Table 4Results from the meta-analysis.ExpositionGroup (Number of studies)Type of studyOR/RR (95% CI)I^2^25(OH)DAll (n = 29)Case-control0.65 (0.56--0.76)40.87%All (n = 4)Cohort0.85 (0.74--0.98)3.56%ER+ (n = 5)Case-control0.98 (0.85--1.13)0%ER-- (n = 5)Case-control0.86 (0.64--1.15)15.60%Postmenopausal (n = 19)Case-control0.74 (0.59--0.93)13.16%Postmenopausal (n = 3)Cohort1.15 (0.59--2.23)8%Premenopausal (n = 9)Case-control0.63 (0.49--0.80)8.37%Dietary vitamin DAll (n = 8)Case-control0.91 (0.72--1.17)30.73%All (n = 5)Cohort1.00 (0.93--1.07)0%Postmenopausal (n = 4)Case-control0.78 (0.68--0.90)0%Postmenopausal (n = 5)Cohort0.95 (0.83--1.09)19.13%Premenopausal (n = 5)Case-Control0.65 (0.52--0.82)0%Premenopausal (n = 3)Cohort1.01 (0.86--1.18)0%Vitamin D supplementsAll (n = 5)Case-control0.78 (0.63--0.98)25.94%All (n = 2)Cohort1.06 (0.90--1.25)0%Total Vitamin D intake (dietary + supplements)All (n = 4)Case-control0.84 (0.68--1.05)18.65%All (n = 2)Cohort0.93 (0.86--1.02)0%Postmenopausal (n = 5)Cohort0.94 (0.87--1.02)17.64%Premenopausal (n = 3)Cohort0.90 (0.72--1.12)10.83%

Four cohort studies^[@CR75],[@CR78]--[@CR80]^ provided results on 25(OH)D and breast cancer relationship, from which we obtained a pooled RR of 0.85 (95% CI:0.74--0.98).

We also analyzed the relationship between 25(OH) D and breast cancer, stratifying results by hormonal receptors (ER+/ER−) and menopausal status (postmenopausal or premenopausal). Regarding hormonal receptors (Table [4](#Tab4){ref-type="table"}), we have found only one cohort study^[@CR80]^ and five case-control studies^[@CR19],[@CR32],[@CR33],[@CR42],[@CR45]^. In both cases (ER+ and ER− tumors) statistical significance was not reached. With respect to menopausal status (Table [4](#Tab4){ref-type="table"}), we obtained a protective effect in both groups: nineteen case-control studies targeted postmenopausal women^[@CR18],[@CR21],[@CR28],[@CR30],[@CR34]--[@CR36],[@CR38],[@CR41],[@CR47],[@CR49],[@CR51],[@CR55],[@CR60],[@CR81]^ with a pooled OR of 0.74 (95%CI: 0.59--0.93), and nine focused on premenopausal^[@CR21],[@CR30],[@CR34],[@CR35],[@CR38],[@CR49],[@CR51],[@CR55],[@CR60]^ obtaining a pooled OR of 0.63 (95%CI: 0.49--0.80) (Fig. [3a](#Fig3){ref-type="fig"}). When the sensitivity analysis was carried out including only nested case-control studies, the protective vitamin D -- breast cancer association persisted only in the premenopausal group (Fig. [3b](#Fig3){ref-type="fig"}, Supplementary Table [1](#MOESM1){ref-type="media"}). On the other hand three cohorts studies analyzed separately postmenopausal women^[@CR79],[@CR81]^ without reaching statistical significance (OR = 1.15 (0.59--2.23)).Figure 3(**a**) Forest plot for the relationship between 25(OH)D and premenopausal breast cancer in case control studies. (**b**) Forest plot for the relationship between 25(OH)D and premenopausal breast cancer in nested case control studies.

Relationship between 1,25(OH)2D and breast cancer {#Sec8}
-------------------------------------------------

Three case-control studies^[@CR25],[@CR37],[@CR39]^ examined the relationship between circulating 1,25(OH)2D and breast cancer; significant association was not found either in the whole analysis (pooled OR = 0.61 (0.33--1.16)) or in postmenopausal women (combined OR = 1.28 IC 95%: 0.98--1.67)^[@CR36],[@CR37]^.

Relationship between dietary vitamin D and breast cancer {#Sec9}
--------------------------------------------------------

We found eight case-control studies^[@CR24],[@CR38],[@CR40],[@CR50],[@CR52],[@CR53],[@CR57],[@CR64]^ on the relationship between dietary vitamin D and breast cancer with a pooled OR of 0.91 (95%CI: 0.72--1.17) (Table [4](#Tab4){ref-type="table"}, Supplementary Fig. [2a](#MOESM1){ref-type="media"}). In addition, by combining five cohort studies^[@CR66],[@CR68],[@CR70]--[@CR72]^ we obtained a RR of 1.00 (95% CI 0.93--1.07) (Table [4](#Tab4){ref-type="table"}, Supplementary Fig. [2b](#MOESM1){ref-type="media"}).

When stratifying by menopausal status, four case-control^[@CR38],[@CR40],[@CR53],[@CR64]^ and five cohort studies^[@CR66],[@CR73],[@CR74],[@CR76],[@CR77]^ assessed the risk of breast cancer in postmenopausal women. The pooled OR for case-control studies was 0.78 (95%CI: 0.68--0.90) and the pooled RR for cohort studies was 0.95 (95%CI: 0.83--1.09) (Table [4](#Tab4){ref-type="table"}). In both analyses, Egger test rejected the possibility of small study bias (p = 0.536 in case-control studies and p = 0.68 in cohort studies). On the other hand, five case-control studies^[@CR17],[@CR38],[@CR40],[@CR53],[@CR63]^ and three cohort studies^[@CR66],[@CR73],[@CR77]^ targeted premenopausal women; the pooled OR was 0.65 (95%CI: 0.52--0.82) for case-control studies and the RR for cohort studies was 1.01 (95% CI: 0.86--1.18) (Table [4](#Tab4){ref-type="table"}).

Relationship between supplements of vitamin D and breast cancer {#Sec10}
---------------------------------------------------------------

We identified five case-control studies^[@CR23],[@CR24],[@CR43],[@CR52],[@CR65]^ and two cohort studies^[@CR67],[@CR71]^ that had evaluated the association between supplements of vitamin D and breast cancer risk. The pooled OR and RR were 0.78 (95% CI: 0.63--0.98) and 1.06(95% IC: 0.90--1.25) respectively (Table [4](#Tab4){ref-type="table"}). Regarding menopausal status, Kim *et al*.^[@CR41]^ published a study on five different populations of postmenopausal women; when combining all five results, we found no significant association (OR: 0.82 95%CI: 0.49--1.35).In addition, we found two case-control studies^[@CR26],[@CR54]^ focused on premenopausal women obtaining a weak protection (pooled OR 0.89 95%CI (0.84--0.95)).

Relationship between total vitamin D intake (dietary and supplements) and breast cancer {#Sec11}
---------------------------------------------------------------------------------------

Finally, we found two cohort studies^[@CR69],[@CR71]^ and four case control studies^[@CR23],[@CR24],[@CR38],[@CR64]^ on vitamin D intake (dietary plus supplements) and breast cancer risk, providing no separate results on dietary/supplemented vitamin D origin. We obtained a combined RR = 0.93 (95% CI: 0.86--1.02) for cohort studies, and a combined OR = 0.84 (95% CI: 0.68--1.05) for case-control studies. Five cohort studies^[@CR69],[@CR73],[@CR74],[@CR76],[@CR77]^ provided results on postmenopausal women (RR = 0.94 95% CI: 0.87--1.00) and three cohort studies^[@CR69],[@CR73],[@CR77]^ on about premenopausal women (RR = 0.90 95% CI: 0.72--1.12) (Table [4](#Tab4){ref-type="table"}). Only two case-control studies provided results according menopausal status^[@CR38],[@CR64]^ without being significant in both groups.

Discussion {#Sec12}
==========

According to our results, 25(OH)D levels were associated with smaller risk of breast cancer in both case-control and cohort studies; these results were consistent on premenopausal women for case-control studies but could not be analyzed for cohort studies. Results for the relationships between breast cancer and dietary vitamin D or between breast cancer and vitamin D supplements, however, showed a protective association only in case-control studies.

In relation to the influence of vitamin D on breast cancer development prospective (cohort and nested case-control) and case control studies tend to show discrepant results: case-control studies usually show a protective effect while prospective studies rarely find it^[@CR87]^. This discrepancy might be the result of several factors: Firstly, it is well known that prospective studies are less prone to be affected by both information and reverse-causation bias. Secondly, several authors highlight the season when the vitamin D measurement was made as a potential limitation of case-control studies. Eliassen *et al*.^[@CR33]^ in a nested case-control study found an inverse association between serum 25(OH) D levels and breast cancer limited only to summer measures. It can be assumed that people with low vitamin D levels in summer would also have low levels year-round; therefore, vitamin D levels in summer would be more adequate for analyzing vitamin D -- breast cancer relationship than vitamin D levels in any other moment of the year.

When stratifying by menopausal status, our meta-analysis shows a consistent protective effect of 25(OH) D in both case-control and nested case-control studies, but only in premenopausal women. There are different explanations for the influence of menopausal status in the relationship between vitamin D and breast cancer. One of them may be related to the joint relationship between vitamin D and insulin-like growth factors (IGFs). IGF-I is a mitogenic and antiapoptotic peptide that can stimulate the proliferation of breast epithelial cells, increasing the risk of [neoplastic]{.ul} transformation^[@CR88],[@CR89]^. The active vitamin D metabolite is able to block the mitogenic effects of IGF-I, leading to a decrease in proliferation and an increase in apoptosis^[@CR90]^. As there is a physiological decline of the IGF with aging^[@CR91]^, the interaction between IGF pathways and vitamin D is likely to be stronger for premenopausal than for postmenopausal women, leading to greater risk reduction in premenopausal breast cancer^[@CR73],[@CR92]^. Finally, high levels of vitamin D may reduce progesterone and estradiol, providing a potential mechanism for reducing breast cancer risk in young women^[@CR93]^.

Previous meta-analyses of prospective studies showed contradictory results. Kim *et al*.^[@CR13]^ (who included 24 studies, 14 of those having measured serum 25(OH)D) found a slightly stronger inverse association among premenopausal than among postmenopausal women but without significant differences, whereas in the meta-analysis of Bauer *et al*.^[@CR8]^ (nine studies included) the inverse association was only observed in postmenopausal women. In our meta-analysis, new prospective studies^[@CR31],[@CR33],[@CR41],[@CR56],[@CR58],[@CR59],[@CR67],[@CR78]--[@CR81],[@CR94]^ not included in previous reviews, were added and this fact may explain the differences in the results.

Concerning hormonal receptors (ER+/ER−), the relationship with breast cancer remains controversial. On the one hand, a decreased risk in ER+ would be expected, since it seems that sensitivity to 1,25(OH)2D is generally reported as being higher in breast cancer cells that express the estrogen receptor than in those that do not^[@CR93],[@CR95]^. It has been demonstrated that treating breast cancer cells ER+ with 1,25(OH)D3 induces a cell cycle shutdown in GO/G1^[@CR3],[@CR96]^. On the other hand, two-thirds of triple negative tumors express VDR^[@CR97]^ and it has been demonstrated that VDR expression is inversely associated with more aggressive breast cancer^[@CR98]^. In consonance with previous epidemiological studies^[@CR32],[@CR33],[@CR42],[@CR45]^, our study does not reach significant differences when the analysis was performed separately in ER+ or ER− subgroups. However, other studies found a decreased risk of ER− breast cancer regarding the serum levels of 25 (OH) D^[@CR18],[@CR60]^.

No relationship is found between the level of circulating 1,25(OH)2D and breast cancer. This result is consistent with previous studies^[@CR9]^, while Janowsky *et al*.^[@CR39]^ found an inverse association. Several authors consider that 1,25(OH)2D is not a good indicator of vitamin D status: First, 1,25(OH)2D's half-life is only 4--6 h, whereas 25(OH)D's half-life is 3 weeks; second, 1,25(OH)2D is influenced by many factors^[@CR10]^, for instance, it can be elevated in patients with vitamin D deficiency as a result of hyperparathyroidism^[@CR12],[@CR99]^; finally, as 1,25(OH)2D is metabolized by 1-α -hydroxylase in breast tissue, plasma levels may not adequately represent breast tissue levels^[@CR12],[@CR100]^.

We do not find a relationship between vitamin D intake and breast cancer in the overall analysis. In contrast, when stratifying by menopausal status, a protective effect is observed in case-control studies in both premenopausal and postmenopausal women, whereas this association is not present in cohort studies. On the other hand, when analyzing the influence of vitamin D supplements on breast cancer risk, we find a borderline protective effect.

In the relationship between vitamin D intake (dietary and/or supplements) and breast cancer, most observational studies showed non-significant differences; only two articles^[@CR17],[@CR53]^ found a protective association. In a previous meta-analysis^[@CR13]^, this association was not significant for either vitamin D intake or supplements.

A probable explanation for the lack of association observed in the analysis of dietary intake or supplements compared to the 25(OH)D levels may be that the main source of vitamin D is sunlight rather than food or supplements.

In addition, the French E3N Cohort Study^[@CR12]^ reported that high vitamin D intake is associated with lower breast cancer risk in regions with high ultraviolet solar radiance. These results suggested that the total amount of vitamin D needed to reach a protective effect on breast cancer is too high to be achieved in regions with low ultraviolet radiance. Under these circumstances, as the vitamin D intake has to be higher than the usually recommended, it could eventually lead to side effects such as hypercalcemia, constipation or muscle weakness.

Our study has some limitations; firstly each article uses different cutoff points according to serum levels of vitamin D. To analyze it we restricted our analysis to the comparison between the highest vs. lowest category of exposure. This analysis strategy does not allow for a dose-response analysis. Moreover, we carried out a sensitivity analysis excluding one study at a time, showing that no single study substantially affected the pooled RR/OR. Secondly, there is huge variability in the literature on the type of vitamin D studied, which makes it difficult to perform the analysis. In addition, levels of vitamin D depend on the season, so it would be advisable to take all samples at the same time, or at least refer to when they were collected^[@CR75]^. Thirdly, case-control studies are more prone to methodological issues, such as recall and selection biases, which limits the strength and quality of evidence. However, about half of the case-control studies included in our meta-analysis are nested in cohort studies, which minimizes the possibility of introducing biases. Finally, breast cancer is a heterogeneous disease and it is possible that vitamin D only affects certain breast cancer subtypes. However, this aspect has been scarcely studied in primary articles, so we have not been able to analyze it in the present meta-analysis.

Despite these limitations, our study also has several strengths; first, we have gathered all the observational studies published in the last twenty years. In addition, we have focused the analysis on different types of vitamin D exposure (diet, supplements and blood-levels of 25(OH) D and 1,25(OH)2D) whereas other meta-analyses are only focused on 25(OH)D levels^[@CR9],[@CR10],[@CR16],[@CR99]^ or vitamin D intake^[@CR12]^. This strategy allows us to obtain a more detailed analysis of the relationship between vitamin D and breast cancer.

In conclusion, our meta-analysis supports the hypothesis that high serum levels of 25(OH) vitamin D has a protective effect on breast cancer risk in premenopausal women; we cannot draw the same conclusion regarding vitamin D intake or supplements of vitamin D since the number of studies are still limited and publication biases cannot be excluded.
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